Lipase
breaks down fats into free fatty acids and glycerol
The exocrine pancreas produces 3 main types of enzymes, which begin to digest macronutrients in the duodenum.
breaks down fats into free fatty acids and glycerol
breaks down proteins into amino acids
breaks down carbohydrates into monosaccharides and disaccharides
Under normal physiological conditions, the pancreas secretes anywhere from 480,000 to 960,000 lipase units per meal—with an average of about 720,000. Steatorrhea* is observed when pancreatic enzyme output drops below ~10% of the normal range.5,6
*Steatorrhea: ≥7 g of fecal fat per day while consuming 100 g of dietary fat per day in the context of a 72-hour stool test.2
EPI (exocrine pancreatic insufficiency) is a condition caused by inadequate production, delivery, or activity of pancreatic enzymes needed for normal digestion.7,8
When the exocrine function of the pancreas is compromised, it can result in maldigestion and malabsorption, which can lead to malnutrition.
Patients with EPI may present with signs and symptoms similar to those of other GI disorders, so it’s important to assess specific clinical features.3
CREON® (pancrelipase) delayed-release capsules are indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.
Please see full Prescribing Information.
US-CREO-230452
References: 1. CREON [package insert]. AbbVie Inc. 2. Fieker A, Philpott J, Armand M. Enzyme replacement therapy for pancreatic insufficiency: present and future. Clin Exp Gastroenterol. 2011;4:55-73. 3. Alkaade S, Vareedayah AA. A primer on exocrine pancreatic insufficiency, fat malabsorption, and fatty acid abnormalities. Am J Manag Care. 2017;23(12)(suppl):S203-S209. 4. Mandel AL, Breslin PA. High endogenous salivary amylase activity is associated with improved glycemic homeostasis following starch ingestion in adults. J Nutr. 2012;142(5):853-858. doi:10.3945/jn.111.156984 5. Keller J, Layer P. Human pancreatic exocrine response to nutrients in health and disease. Gut. 2005;54(suppl 6):vi1-vi28. 6. DiMagno EP, Go VLW, Summerskill WHJ. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. N Engl J Med. 1973;288(16):813-815. 7. Durie P, Baillargeon J-D, Bouchard S, Donnellan F, Zepeda-Gomez S, Teshima C. Diagnosis and management of pancreatic exocrine insufficiency (PEI) in primary care: consensus guidance of a Canadian expert panel. Curr Med Res Opin. 2018;34(1):25-33. 8. Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol. 2013;19(42):7258-7266. 9. Zuvarox T, Belletieri C. Malabsorption syndromes. In: StatPearls. StatPearls Publishing; 2021. 10. Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacotherapy. Pharmacotherapy. 2007;27(6):910-920. 11. Lindkvist B, Phillips ME, Domínguez-Muñoz JE. Clinical, anthropometric and laboratory nutritional markers of pancreatic exocrine insufficiency: prevalence and diagnostic use. Pancreatology. 2015;15(6):589-597. 12. Domínguez-Muñoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep. 2007;9(2):116-122.